TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33184931

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg for 6 weeks
Number of subjects: 4775
Study: 36476310

Group type: EXPERIMENTAL
Intervention: ACME (Antrodia Cinnamomea mycelia extract) 250 mg daily for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo capsule daily for 12 weeks
Number of subjects: 44
Study: 34126249

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab treatment for neovascular AMD
Number of subjects: 406
Study: 36243220

Group type: COMPARATOR
Intervention: Resistance training in normoxia (RTN; n = 17)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Resistance training in hypoxia (RTH; n = 13)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CON; n = 20)
Number of subjects: 50
Study: 34078180

Group type: EXPERIMENTAL
Intervention: Positive stereotype
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Negative stereotype
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study: 32323609

Group type: EXPERIMENTAL
Intervention: KP-100 (recombinant human hepatocyte growth factor) administered intrathecally
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: KP-100
Number of subjects: 43
Study: 35959712

Group type: EXPERIMENTAL
Intervention: Large particle (LP) size graft
Number of subjects: 22

Group type: COMPARATOR
Intervention: Small particle (SP) size graft
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study: 33332919

Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB) with 10 mL of 0.375% ropivacaine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group with 0.9% saline
Number of subjects: 85
Study: 32553932

Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase
Number of subjects: 600

Group type: COMPARATOR
Intervention: Routine pPCI
Number of subjects: 600
Study: 35268018

Group type: EXPERIMENTAL
Intervention: Mindful eating (MIND)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Eating without distractions (CON-D)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No instructions (CON-I)
Number of subjects: 99
Study: 33966699

Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound (DTF-DB and DE-DB measurements)
Number of subjects: 0
Study: 33310801

Group type: EXPERIMENTAL
Intervention: Fixed-dose antihypertensive monotherapy
Number of subjects: 2423

Group type: EXPERIMENTAL
Intervention: Low-dose monotherapy (defined daily dose: 0.5 units)
Number of subjects: 2423
Study: 36100413

Group type: EXPERIMENTAL
Intervention: 20% glucose solution
Number of subjects: 65

Group type: COMPARATOR
Intervention: 50% glucose solution
Number of subjects: 65
Study: 34134574

Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with TPF induction chemotherapy (5-fluorouracil, cisplatin, and docetaxel)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TPF induction chemotherapy alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with TPF induction chemotherapy
Number of subjects: 120
Study: 32028982

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Procedure
Number of subjects: 50
Study: 32533314

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 35538465

Group type: EXPERIMENTAL
Intervention: Group/Individual CRAFT
Number of subjects: 249

Group type: COMPARATOR
Intervention: Self-administered CRAFT (control group)
Number of subjects: 249
Study: 34866887

Group type: EXPERIMENTAL
Intervention: Shoulder Pain Prevention Program (SPPP) with one instruction session and a refresher session 4 weeks later with a physical therapist
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Shoulder Pain Prevention Program (SPPP) with a 4-week series of 2-hour group classes taught by a physical therapist and peer mentor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (historical controls from a 3-year observational study)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 100
Study: 34971475

Group type: EXPERIMENTAL
Intervention: Carboxytherapy at a flow rate of 30 ml/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carboxytherapy at a flow rate of 60 ml/min
Number of subjects: 80
Study: 34154520

Group type: EXPERIMENTAL
Intervention: Partners for Change Outcome Management System (PCOMS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study: 32619832

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemoradiotherapy (fluorouracil and oxaliplatin)
Number of subjects: 52
Study: 36054737

Group type: COMPARATOR
Intervention: Mealtime ultra-rapid lispro (URLi)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Postmeal ultra-rapid lispro (URLi)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Lispro
Number of subjects: 716
Study: 34360315

Group type: EXPERIMENTAL
Intervention: ProLiSMental psychoeducational intervention (4 or 8 weekly sessions of 90 or 45 min)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waiting list control group (WLCG)
Number of subjects: 38
Study: 32485323

Group type: EXPERIMENTAL
Intervention: Parenting programme intervention
Number of subjects: 552
Study: 33242705

Group type: EXPERIMENTAL
Intervention: Palliative and end-of-life care education
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Teaching strategies
Number of subjects: 95
Study: 32114728

Group type: EXPERIMENTAL
Intervention: Ulinastatin + Glutamine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional Treatment
Number of subjects: 32
Study: 35043556

Group type: EXPERIMENTAL
Intervention: 12-month continuity of care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing (control)
Number of subjects: 100
Study: 34675886

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using IPro2 device
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 120
Study: 32840920

Group type: EXPERIMENTAL
Intervention: RNA in situ hybridization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control sections
Number of subjects: 100
Study: 33041022

Group type: EXPERIMENTAL
Intervention: HYD diet (75 mg/kg Zn from HYD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control diet (75 mg/kg Zn from zinc sulfate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FRHYD (40% of ad libitum feed intake and HYD diet)
Number of subjects: 24

Group type: COMPARATOR
Intervention: FRCON (40% of ad libitum feed intake and control diet)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FR treatments (40% of ad libitum feed intake)
Number of subjects: 24

Group type: COMPARATOR
Intervention: AL treatments (ad libitum fed)
Number of subjects: 24
Study: 35332591

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with birch and 5-grass allergen extracts (10,000 SQ units/ml, ALK-Abelló)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with birch and placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with 5-grass and placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 33723066

Group type: EXPERIMENTAL
Intervention: Testosterone gel administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel administration
Number of subjects: 60
Study: 32171667

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 90 min exposure to 100% O2 at 2 atmospheres absolute, daily for 5 days a week for 4 weeks before surgery and 10 additional sessions after first-stage surgery
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard surgical procedure without HBOT (Control)
Number of subjects: 21
Study: 35948268

Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain polyunsaturated fatty acid supplementation (4.2 g per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 28
Study: 33826132

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598

Group type: EXPERIMENTAL
Intervention: All-bari-2-mg-AD
Number of subjects: 1598
Study: 33351042

Group type: EXPERIMENTAL
Intervention: Digoxin (n=80; mean dose 161 μg/d)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bisoprolol (n=80; mean dose 3.2 mg/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 160
Study: 34933097

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control (non-obese patients)
Number of subjects: 299
Study: 32311675

Group type: EXPERIMENTAL
Intervention: Externally heated jacket (HEAT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standardized tracksuit top (CON)
Number of subjects: 10
Study: 32419128

Group type: EXPERIMENTAL
Intervention: Manual chest compression (CC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Compression with CPRMeter
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Compression with LifeLine ARM device
Number of subjects: 35
Study: 34614363

Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 32694183

Group type: EXPERIMENTAL
Intervention: Nocturnal noninvasive ventilation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Long-term oxygen therapy (nasal cannula)
Number of subjects: 14
Study: 35607776

Group type: EXPERIMENTAL
Intervention: NeuroEPO (nasally administered recombinant EPO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NeuroEPO
Number of subjects: 34
Study: 32876054

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (DLC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Comparison of complications
Number of subjects: 176

Group type: COMPARATOR
Intervention: Comparison of hospital stay and total costs
Number of subjects: 176
Study: 35208601

Group type: EXPERIMENTAL
Intervention: Needleless Jet Anesthesia (JA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Syringe (CS)
Number of subjects: 30
Study: 32049937

Group type: EXPERIMENTAL
Intervention: Weekly teriparatide (WT) from 1 week to 6 months postoperatively
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bisphosphonate (BP)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bone contact status (BC+)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bone contact status (BC-)
Number of subjects: 104
Study: 33664159

Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) gait training
Number of subjects: 2
Study: 32541882

Group type: EXPERIMENTAL
Intervention: Community-based intervention involving regular telephone calls and home visits
Number of subjects: 204
Study: 33738492

Group type: EXPERIMENTAL
Intervention: Rituximab + LEF
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo + LEF
Number of subjects: 140
Study: 32236402

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention + placebo
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention + n-3 PUFA
Number of subjects: 269

Group type: COMPARATOR
Intervention: n-3 PUFA supplementation alone
Number of subjects: 269
Study: 36229121

Group type: EXPERIMENTAL
Intervention: PCIT-CU
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard PCIT
Number of subjects: 43
Study: 35395021

Group type: EXPERIMENTAL
Intervention: Self-referred message
Number of subjects: 264

Group type: COMPARATOR
Intervention: Family-referred message
Number of subjects: 264
Study: 34476612

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Changes in core temperature at 25 and 30 min after SA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100
Study: 33789028

Group type: EXPERIMENTAL
Intervention: Artesunate‐Amodiaquine (AS+AQ)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Artemether‐Lumefantrine (AL)
Number of subjects: 712
Study: 35465375

Group type: EXPERIMENTAL
Intervention: Chloroxylenol antiseptic soap bath before operation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard ward pre-operative preparation procedures
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chloroxylenol antiseptic soap bath
Number of subjects: 96
Study: 32032738

Group type: EXPERIMENTAL
Intervention: Anodal tDCS targeting the auditory cortex
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study: 35613009

Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 120
Study: 33055078

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg intravenous, two infusions 4 weeks apart)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 91
Study: 32602828

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with a tumor radiation-absorbed dose greater than or equal to 100 Gy (n = 67)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with optimal agreement (n = 24)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with tumor radiation-absorbed dose greater than or equal to 100 Gy and optimal agreement
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 121
Study: 34157632

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1500 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 33395597

Group type: EXPERIMENTAL
Intervention: Nonfatal opioid overdose
Number of subjects: 8370
Study: 32567708

Group type: EXPERIMENTAL
Intervention: 10 sessions of ISTDP with the use of challenge
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10 sessions of ISTDP without the use of challenge
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study: 33864548

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) - 10 sessions (n=31)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) (n=33)
Number of subjects: 64
Study: 33400330

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 383
Study: 32271271

Group type: EXPERIMENTAL
Intervention: Clareon IOL
Number of subjects: 139

Group type: COMPARATOR
Intervention: Tecnis PCB00 IOL
Number of subjects: 139
Study: 36006808

Group type: EXPERIMENTAL
Intervention: Deferred stenting (n = 594)
Number of subjects: 1205
Study: 32915043

Group type: EXPERIMENTAL
Intervention: hypCPT (cognitive processing therapy + hypnosis)
Number of subjects: 45

Group type: COMPARATOR
Intervention: ssmCPT (sleep and psychiatric symptom monitoring plus cognitive processing therapy)
Number of subjects: 45
Study: 35294683

Group type: EXPERIMENTAL
Intervention: Steps to Success
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (existing home visiting program)
Number of subjects: 594
Study: 32432718

Group type: EXPERIMENTAL
Intervention: Polymer-free, biolimus A9-eluting drug-coated stent with 1-month dual antiplatelet therapy
Number of subjects: 2432

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 2432
Study: 32894418

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral stress management intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Psychoeducation control group
Number of subjects: 99
Study: 32778489

Group type: EXPERIMENTAL
Intervention: 0.2% polidocanol + 70% hypertonic glucose (HG)
Number of subjects: 115

Group type: COMPARATOR
Intervention: 75% hypertonic glucose (HG) alone
Number of subjects: 115
Study: 35750555

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 92
Study: 33508626

Group type: EXPERIMENTAL
Intervention: 3D digital measurement using a handheld scanner
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional measurement using electronic digital caliper
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3D digital measurement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional measurement
Number of subjects: 100
Study: 34984839

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI, 80 U)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 32979620

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) prior to TBLB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo prior to TBLB
Number of subjects: 50
Study: 32384055

Group type: EXPERIMENTAL
Intervention: MYLO (Manage Your Life Online)
Number of subjects: 112

Group type: COMPARATOR
Intervention: ELIZA
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both MYLO and ELIZA
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: MYLO
Number of subjects: 112
Study: 33073298

Group type: EXPERIMENTAL
Intervention: Adipose tissue stem cell-derived exosomes gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 25
Study: 34550563

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 µg kg-1 h-1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (0.5 ml kg-1 h-1)
Number of subjects: 80
Study: 34323574

Group type: EXPERIMENTAL
Intervention: Tailored Motivational Interviewing (TMI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Services as usual (Control)
Number of subjects: 19
Study: 33176942

Group type: EXPERIMENTAL
Intervention: JUUL System (JS) in four flavors (Virginia Tobacco, Mango, Mint, Creme, [5.0 % nicotine; 59 mg/mL])
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: JUUL System (JS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mint and Mango JS flavors
Number of subjects: 66
Study: 35927518

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 36410666

Group type: EXPERIMENTAL
Intervention: Daily TPTD (20 μg daily)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cyclic TPTD (20 μg daily for 3 months followed by 3 months off)
Number of subjects: 86
Study: 33879849

Group type: EXPERIMENTAL
Intervention: Dopamine (n = 13)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hypotensive infants (n = 36)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-hypotensive infants (n = 53)
Number of subjects: 89
Study: 36432461

Group type: EXPERIMENTAL
Intervention: Daily walnut consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Academic stress
Number of subjects: 0
Study: 33090462

Group type: EXPERIMENTAL
Intervention: +EBR (10 nM EBR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: -EBR (0 nM EBR)
Number of subjects: 0
Study: 32404535

Group type: EXPERIMENTAL
Intervention: Virtual reality with regular training (VRRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular training (RT)
Number of subjects: 0
Study: 32643561

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 256
Study: 33244038

Group type: EXPERIMENTAL
Intervention: PSA test without sojourn time correction
Number of subjects: 20796

Group type: EXPERIMENTAL
Intervention: PSA test with sojourn time correction
Number of subjects: 20796
Study: 35459100

Group type: EXPERIMENTAL
Intervention: Prehabilitation with a preoperative exercise and education program delivered over 4 to 8 weeks before surgery.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Prehabilitation with a preoperative exercise and education program.
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care alone (control group).
Number of subjects: 172
Study: 32735653

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (alone or with actoxumab)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Control (placebo or actoxumab)
Number of subjects: 1588
Study: 32533012

Group type: EXPERIMENTAL
Intervention: TT genotype of rs165728
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TT genotype of rs174699
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GG genotype at rs4680 G > A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CC genotype at rs4633
Number of subjects: 0

Group type: COMPARATOR
Intervention: rs174675 T and rs933271 C alleles
Number of subjects: 0
Study: 36362620

Group type: EXPERIMENTAL
Intervention: Intensified clinical pharmacological/pharmaceutical care program
Number of subjects: 202
Study: 34244807

Group type: EXPERIMENTAL
Intervention: QI coaching
Number of subjects: 855

Group type: COMPARATOR
Intervention: Communication training
Number of subjects: 855

Group type: COMPARATOR
Intervention: Combined intervention
Number of subjects: 855
Study: 33710466

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (measured as number of cigarettes smoked per day)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (specifically rs1051730 T alleles in ever smokers)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group (never smokers)
Number of subjects: 1008
Study: 33087145

Group type: EXPERIMENTAL
Intervention: Re-esterified DHA (975 mg for 30 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Re-esterified DHA
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study: 35701734

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33842996

Group type: EXPERIMENTAL
Intervention: OFD+AA/PRF
Number of subjects: 20

Group type: COMPARATOR
Intervention: OFD+PRF
Number of subjects: 20
Study: 33596968

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided ESP block with 40 ml 0.25% levo-bupivacaine (20 ml each side) post induction of general anaesthesia and before surgical incision.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standardised analgesic protocol (same for both groups).
Number of subjects: 50